IMD business school for management and leadership courses

Merck & Co. is integrating AI across the drug development lifecycle to enhance speed, precision, and compliance. In drug design, Merck is an early user of Variational AI’s generative AI models to create molecules that meet a target product profile. Robotic and automated labs help validate in-silico predictions rapidly, shortening the time from hypothesis to result. 

Large language models (LLMs) are deployed enterprise-wide to automate regulatory documentation, compress compliance timelines, and augment scientific reasoning. Merck’s proprietary GPTeal platform gives more than 50,000 employees secure access to leading LLMs for productivity gains across R&D, clinical, and corporate functions. In manufacturing, digital twin technology, computer vision, and 3D printing converge at new smart facilities like the $1bn Durham vaccine plant, enabling real-time quality control and production scaling. 

Merck’s Code of Digital Ethics, built on seven pillars, guides development and deployment to ensure fairness, transparency, privacy, and safety. Together, these initiatives reflect Merck’s commitment to a digitally enabled, ethically sound future of pharmaceutical innovation.